LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

LLY

1,085.59

+1.84%↑

JNJ

231.35

+0.49%↑

ABBV

215.42

+1.31%↑

UNH

384.08

+1.74%↑

MRK

120.33

+0.58%↑

Home・Lista de Ações・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

11.64

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

11.16

Máximo

11.72

Indicadores-chave
By Trading Economics
Rendimento	227M
Vendas	139M
P/E Médio do Setor	4.522 50.102
Margem de lucro	163.843
Funcionários	1,796
EBITDA	1.3M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+70.21% upside

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	2.1B
Abertura anterior	11.64
Fecho anterior	11.64

Sentimento de Notícias

By Acuity

10%

90%

7 / 344 Ranking em Healthcare

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mai. de 2026, 21:33 UTC

Ganhos

Correction to Salesforce 1Q Sales, Profit Rise Article

27 de mai. de 2026, 21:00 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare Agrees to Buy The College of Health Care Professions

27 de mai. de 2026, 20:18 UTC

Ganhos

Salesforce 1Q Sales, Profit Rise Amid Agentforce Efforts

27 de mai. de 2026, 23:49 UTC

Conversa de Mercado

Nikkei Might Decline Amid Uncertainty Over Potential U.S.-Iran Peace Deal -- Market Talk

27 de mai. de 2026, 23:39 UTC

Conversa de Mercado

Congo Copper, Cobalt Mining Not yet Seen Affected by Ebola Outbreak -- Market Talk

27 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Infratil's Longroad Energy Considers Data-Center Strategy -- Market Talk

27 de mai. de 2026, 23:34 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

27 de mai. de 2026, 23:08 UTC

Conversa de Mercado

Chinese Coal-Mine Disruptions Could Be Major Supply Shock for Global Markets -- Market Talk

27 de mai. de 2026, 22:21 UTC

Conversa de Mercado

Salesforce Lays Out AI Monetization Strategy -- Market Talk

27 de mai. de 2026, 21:29 UTC

Ações em Alta

Stocks to Watch: Marvell Technology, PDD, Zscaler -- WSJ

27 de mai. de 2026, 21:08 UTC

Ganhos

Marvell's Data-Center Boom Powers Earnings Beat. Its Stock Surges. -- Barrons.com

27 de mai. de 2026, 21:02 UTC

Ganhos

Salesforce Stock Slides on Mixed Results. CFO Touts New Pricing Model. -- Barrons.com

27 de mai. de 2026, 20:59 UTC

Aquisições, Fusões, Aquisições de Empresas

What to Know About Pasqal, the Quantum Start-Up Going Public Soon -- Barrons.com

27 de mai. de 2026, 20:55 UTC

Ganhos

Snowflake Stock Jumps 34%. How Amazon and an Earnings Beat Are Fueling the Gains. -- Barrons.com

27 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de mai. de 2026, 20:48 UTC

Ganhos

Marvell's Data-Center Boom Powers Earnings Beat -- and a Big Stock Surge -- Barrons.com

27 de mai. de 2026, 20:45 UTC

Ganhos

Marvell Stock Jumps on Earnings. Data-Center Revenue Is Still Booming. -- Barrons.com

27 de mai. de 2026, 20:34 UTC

Aquisições, Fusões, Aquisições de Empresas

Webster Financial Stockholders Approve Sale to Banco Santander

27 de mai. de 2026, 20:32 UTC

Ganhos

Aquisições, Fusões, Aquisições de Empresas

Synopsys Shares Fall Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

27 de mai. de 2026, 20:32 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare to Acquire The College of Health Care Professions for Undisclosed Terms >HCA

27 de mai. de 2026, 20:32 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare: Eric Bing Will Continue to Lead CHCP as Chancellor and CEO >HCA

27 de mai. de 2026, 20:30 UTC

Ganhos

Snowflake Beats Expectations and Expands AWS Ties Amid Software Sector Turmoil -- Barrons.com

27 de mai. de 2026, 20:30 UTC

Aquisições, Fusões, Aquisições de Empresas

HCA Healthcare Announces Agreement To Acquire The College Of Health Care Professions >HCA

27 de mai. de 2026, 20:22 UTC

Ganhos

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 de mai. de 2026, 20:16 UTC

Ganhos

Salesforce Stock Slides on Mixed Results -- Barrons.com

27 de mai. de 2026, 20:13 UTC

Ganhos

Synopsys Sees 3Q Adj EPS $3.63-Adj EPS $3.69 >SNPS

27 de mai. de 2026, 20:13 UTC

Ganhos

Marvell Revenue Beats Estimates. The Stock Rises. -- Barrons.com

27 de mai. de 2026, 20:13 UTC

Ganhos

Synopsys Sees FY Adj EPS $14.72-Adj EPS $14.80 >SNPS

27 de mai. de 2026, 20:12 UTC

Ganhos

Synopsys Sees FY EPS $2.49-EPS $2.91 >SNPS

27 de mai. de 2026, 20:12 UTC

Ganhos

Synopsys Sees 3Q EPS 84c-EPS 98c >SNPS

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

70.21% parte superior

Previsão para 12 meses

Média 20 USD 70.21%

Máximo 20 USD

Mínimo 20 USD

Com base em 1 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

1 ratings

Comprar

Manter

Vender

Com base em 1 analistas que deram avaliações de ações para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Sentimento

By Acuity

7 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.